PPADS

PPADS is a P2 receptor antagonist, with IC50s of 68 nM (P2X1) and 214 nM (P2X3) . PPADS acts as an ATP (nucleotide) mimetic and competes with ATP for its binding site on P2 receptors. PPADS is also a reversible competitive antagonist of the NAADP receptor. PPADS reverses nociceptive hypersensitivity and reduces the increased NO/NOS system and IL-1β in both peripheral and central steps of nervous system[1][2][3].

Product Specifications

CAS Number

149017-66-3

UNSPSC

12352005

Target

P2X Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ppads.html

Smiles

O=CC1=C(C(C)=NC(/N=N/C2=CC=C(S(=O)(O)=O)C=C2S(=O)(O)=O)=C1COP(O)(O)=O)O

Molecular Formula

C14H14N3O12PS2

Molecular Weight

511.38

References & Citations

[1]Billington RA, et al. PPADS is a reversible competitive antagonist of the NAADP receptor. Cell Calcium. 2007 Jun;41 (6) :505-11. |[2]Brown SG, et al. Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors. Drug Dev Res. 2001 Aug;53 (4) :281-291. |[3]Martucci C, et al. The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain. 2008 Jul;137 (1) :81-95.